From the Research
I strongly advise against taking Vyvanse and tirzepatide together without medical supervision due to potential interactions affecting blood sugar levels and amplified side effects. These medications have different purposes - Vyvanse (lisdexamfetamine) is a stimulant used for ADHD and binge eating disorder, while tirzepatide (Mounjaro, Zepbound) is used for type 2 diabetes and weight management. When taken together, there could be potential interactions affecting blood sugar levels, as Vyvanse may increase blood glucose while tirzepatide works to lower it. Additionally, both medications can affect appetite, potentially causing excessive appetite suppression when combined.
Potential Interactions and Side Effects
- Blood sugar level interactions: Vyvanse may increase blood glucose, while tirzepatide works to lower it 1
- Amplified side effects: nausea, decreased appetite, and cardiovascular effects like increased heart rate or blood pressure changes
- Excessive appetite suppression: both medications can affect appetite, potentially causing excessive appetite suppression when combined
Importance of Medical Supervision
If you have been prescribed both medications, it is crucial to consult your healthcare provider about proper timing, dosing, and monitoring. They may recommend taking the medications at different times of day or adjusting doses to minimize interactions. Only a healthcare provider familiar with your complete medical history can determine if this combination is safe and appropriate for your specific situation. According to a recent study on tirzepatide, it has a favorable safety profile with a low risk of hypoglycemia, but adverse events such as gastrointestinal reactions were frequently reported 2.
Recent Studies on Tirzepatide
Recent studies have shown that tirzepatide is effective in improving glycemic control and weight reduction in patients with type 2 diabetes 1, 3. However, these studies do not provide information on the safety and efficacy of combining tirzepatide with Vyvanse. A study published in 2025 found that tirzepatide resulted in significant weight loss and improved glucose control in adults with type 1 diabetes 3. Another study published in 2023 found that tirzepatide has a favorable safety profile with a low risk of hypoglycemia, but adverse events such as gastrointestinal reactions were frequently reported 2.